Trial Profile

A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CK-3773274 in Healthy Chinese Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Oct 2024 According to a CORXEL media release, Ji Xing Pharmaceuticals name changed to CORXEL.
18 Mar 2022 Results assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of aficamten a selective cardiac myosin inhibitor, in healthy Chinese adult subjects presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
12 Sep 2021 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com